{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:08:24Z","timestamp":1793858904916,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jacc.2020.12.024","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T01:24:10Z","timestamp":1613438650000},"page":"922-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":336,"title":["Cardiac Involvement in Fabry Disease"],"prefix":"10.1016","volume":"77","author":[{"given":"Maurizio","family":"Pieroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Arbustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Camporeale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja Cokan","family":"Vujkovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hagege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Pietil\u00e4-Effati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Namdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2020.12.024_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jacc.2020.12.024_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacc.2020.12.024_bib3","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2020.12.024_bib4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The role of cardiac imaging in the diagnosis and management of Anderson-Fabry disease","volume":"12","author":"Perry","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.12.024_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017","volume":"55","author":"Doheny","year":"2018","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jacc.2020.12.024_bib6","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.jacc.2020.12.024_bib7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","volume":"43","author":"van der Veen","year":"2020","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jacc.2020.12.024_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jacc.2020.12.024_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jacc.2020.12.024_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ymgme.2019.07.012","article-title":"Founder effect of Fabry disease due to p.F113L mutation: clinical profile of a late-onset phenotype","volume":"129","author":"Azevedo","year":"2020","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jacc.2020.12.024_bib12","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2020.12.024_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2020.12.024_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.carpath.2018.11.002","article-title":"Lysosomal storage disorders affecting the heart: a review","volume":"39","author":"Nair","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.jacc.2020.12.024_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.008872","article-title":"Quantitative myocardial perfusion in Fabry disease","volume":"12","author":"Knott","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.12.024_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jacc.2020.12.024_bib17","first-page":"1116","article-title":"Altered sphingolipids metabolism damaged mitochondrial functions: lessons learned from Gaucher and Fabry diseases","volume":"9","author":"Ivanova","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2020.12.024_bib18","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","article-title":"Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease","volume":"172","author":"Chimenti","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2020.12.024_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","article-title":"A\u00a0human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology","volume":"13","author":"Birket","year":"2019","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jacc.2020.12.024_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2020.12.024_bib21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2020.12.024_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.12.024_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jacc.2020.12.024_bib24","first-page":"1","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.jacc.2020.12.024_bib25","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacc.2020.12.024_bib26","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.12.024_bib27","article-title":"Immune-mediated myocarditis in Fabry disease cardiomyopathy","volume":"7","author":"Frustaci","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2020.12.024_bib28","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2020.12.024_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2019.06.073","article-title":"Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy","volume":"299","author":"Limongelli","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2020.12.024_bib30","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","author":"Augusto","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.12.024_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of clinical evolution in prehypertrophic Fabry disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.12.024_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2020.12.024_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-016-0320-1","article-title":"Metabolic progression to clinical phenotype in classic Fabry disease","volume":"43","author":"Spada","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jacc.2020.12.024_bib34","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2020.12.024_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2020.12.024_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2020.12.024_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ckj\/sfy108","article-title":"New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases","volume":"12","author":"Mignani","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2020.12.024_bib38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jacc.2020.12.024_bib39","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","author":"Peterschmitt","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jacc.2020.12.024_bib40","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","article-title":"Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types","volume":"27","author":"Welford","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacc.2020.12.024_bib41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jacc.2020.12.024_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacc.2020.12.024_bib43","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2020.12.024_bib44","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in Fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2020.12.024_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2020.12.024_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217780","article-title":"Efficacy of pentosan polysulfate in in\u00a0vitro models of lysosomal storage disorders: Fabry and Gaucher disease","volume":"14","author":"Crivaro","year":"2019","journal-title":"PLoS One"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720381250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720381250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:39:06Z","timestamp":1760017146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720381250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0735109720381250"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Involvement in Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}